127 related articles for article (PubMed ID: 28842253)
1. Repression of ESR1 transcription by MYOD potentiates letrozole-resistance in ERα-positive breast cancer cells.
Zhang Q; Liu XY; Li S; Zhao Z; Li J; Cui MK; Wang EH
Biochem Biophys Res Commun; 2017 Oct; 492(3):425-433. PubMed ID: 28842253
[TBL] [Abstract][Full Text] [Related]
2. Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness.
Tilghman SL; Townley I; Zhong Q; Carriere PP; Zou J; Llopis SD; Preyan LC; Williams CC; Skripnikova E; Bratton MR; Zhang Q; Wang G
Mol Cell Proteomics; 2013 Sep; 12(9):2440-55. PubMed ID: 23704778
[TBL] [Abstract][Full Text] [Related]
3. AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
O'Hara J; Vareslija D; McBryan J; Bane F; Tibbitts P; Byrne C; Conroy RM; Hao Y; Gaora PÓ; Hill AD; McIlroy M; Young LS
Clin Cancer Res; 2012 Jun; 18(12):3305-15. PubMed ID: 22550166
[TBL] [Abstract][Full Text] [Related]
4. miR-1271 inhibits ERα expression and confers letrozole resistance in breast cancer.
Yu T; Yu HR; Sun JY; Zhao Z; Li S; Zhang XF; Liao ZX; Cui MK; Li J; Li C; Zhang Q
Oncotarget; 2017 Dec; 8(63):107134-107148. PubMed ID: 29291017
[TBL] [Abstract][Full Text] [Related]
5. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A; Brodie AM; Njar VC
Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
[TBL] [Abstract][Full Text] [Related]
6. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of PITX2 Promotes Letrozole Resistance Via Transcriptional Activation of IFITM1 Signaling in Breast Cancer Cells.
Xu YY; Yu HR; Sun JY; Zhao Z; Li S; Zhang XF; Liao ZX; Cui MK; Li J; Li C; Zhang Q
Cancer Res Treat; 2019 Apr; 51(2):576-592. PubMed ID: 30025446
[TBL] [Abstract][Full Text] [Related]
8. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
9. Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis.
Sayeed A; Konduri SD; Liu W; Bansal S; Li F; Das GM
Cancer Res; 2007 Aug; 67(16):7746-55. PubMed ID: 17699779
[TBL] [Abstract][Full Text] [Related]
10. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer.
Torrisi R; Bagnardi V; Pruneri G; Ghisini R; Bottiglieri L; Magni E; Veronesi P; D'Alessandro C; Luini A; Dellapasqua S; Viale G; Goldhirsch A; Colleoni M
Br J Cancer; 2007 Sep; 97(6):802-8. PubMed ID: 17712311
[TBL] [Abstract][Full Text] [Related]
11. Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.
Sabnis GJ; Goloubeva O; Chumsri S; Nguyen N; Sukumar S; Brodie AM
Cancer Res; 2011 Mar; 71(5):1893-903. PubMed ID: 21245100
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
[TBL] [Abstract][Full Text] [Related]
13. Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.
Dabydeen SA; Kang K; Díaz-Cruz ES; Alamri A; Axelrod ML; Bouker KB; Al-Kharboosh R; Clarke R; Hennighausen L; Furth PA
Carcinogenesis; 2015 Jan; 36(1):122-32. PubMed ID: 25421723
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer.
Tokuda E; Seino Y; Arakawa A; Saito M; Kasumi F; Hayashi S; Yamaguchi Y
Breast Cancer Res Treat; 2012 Jun; 133(2):427-36. PubMed ID: 21909982
[TBL] [Abstract][Full Text] [Related]
15. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
Wen J; Li R; Lu Y; Shupnik MA
Oncogene; 2009 Jan; 28(4):575-86. PubMed ID: 18997820
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
17. Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.
Curley MD; Sabnis GJ; Wille L; Adiwijaya BS; Garcia G; Moyo V; Kazi AA; Brodie A; MacBeath G
Mol Cancer Ther; 2015 Nov; 14(11):2642-52. PubMed ID: 26310543
[TBL] [Abstract][Full Text] [Related]
18. Increase in hyaluronic acid degradation decreases the expression of estrogen receptor alpha in MCF7 breast cancer cell line.
Hanoux V; Eguida J; Fleurot E; Levallet J; Bonnamy PJ
Mol Cell Endocrinol; 2018 Nov; 476():185-197. PubMed ID: 29753772
[TBL] [Abstract][Full Text] [Related]
19. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression.
Zhang B; Zhang X; Tang B; Zheng P; Zhang Y
Breast Cancer Res Treat; 2012 Nov; 136(2):399-406. PubMed ID: 23053650
[TBL] [Abstract][Full Text] [Related]
20. Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer.
Muluhngwi P; Klinge CM
Mol Cell Endocrinol; 2017 Nov; 456():76-86. PubMed ID: 28163101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
